Psivant Therapeutics is advancing a paradigm shift in biotechnology by pioneering a physics-driven approach to drug design that is tightly coupled to chemistry and biology research and development. The company's QUAISAR platform is purpose-built to discover novel small molecule therapeutics to address biologically and genetically validated, but previously intractable, protein targets.